Men with a negative prostate MRI followed by a negative systematic prostate biopsy have a low overall long-term risk for high-grade prostate cancer, according to study findings presented at the 22nd annual meeting of the Society of Urologic Oncology.
The retrospective study included 84 men with a negative MRI. On their first standard transrectal 12-core systemic biopsy following MRI, 62 patients (74%) had no cancer detected and 11 (13%) were diagnosed with high-grade prostate cancer, Grant M. Henning, MD, of Washington University School of Medicine in St. Louis, Missouri, and colleagues reported in a poster presentation. The investigators defined high-grade prostate cancer as Gleason grade 7 or higher on biopsy.
The 62 patients with negative findings were monitored for a median of 71.2 months, with 51.2% of patients having at least 5 years of available follow-up data. During the follow-up period, 7 patients (11.3%) were diagnosed with high-grade prostate cancer but none were diagnosed within 3 years ofthe negative MRI and negative biopsy.
“We proposed that patients with persistent clinical concern for [prostate cancer] be reassessed at 3 years following negative MRI and negative systematic biopsy,” the investigators concluded.
PSA levels following the negative MRI were 6.2 and 9.9 ng/mL for patients later found to have a negative biopsy and positive biopsy, respectively, but the difference was not significant.
Henning GM, Vetter JM, Shiang A, Barashi NS, Andriole GL, Kim EH. Long-term risk of high-grade prostate cancer following negative MRI and negative systematic biopsy. Presented at the 22nd annual meeting of the Society of Urologic Oncology, December 1-3, 2021. Poster 147.